← Back to Search

Dietary Supplement

Treatment Arm for Coronavirus

N/A
Waitlist Available
Led By James Veltmeyer, MD
Research Sponsored by Therapeutic Solutions International
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights

Study Summary

This trial will test if a nutritional supplement can help reduce infection risk in people who are likely to get COVID-19.

Eligible Conditions
  • Coronavirus
  • Coronavirus Infection
  • COVID-19

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Prevention of COVID-19
Secondary outcome measures
Safety as determined by presence or absence of Adverse Events and Serious Adverse Events

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment ArmExperimental Treatment1 Intervention
Patients will receive 2 pills of QuadraMune(TM) daily for 12 weeks

Find a Location

Who is running the clinical trial?

Therapeutic Solutions InternationalLead Sponsor
2 Previous Clinical Trials
60 Total Patients Enrolled
James Veltmeyer, MDPrincipal InvestigatorTherapeutic Solutions International
1 Previous Clinical Trials
30 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~103 spots leftby Apr 2025